Connect with us

BIOTECH

What Is Axim Biotechnologies Inc (OTCMKTS:AXIM) Doing In Field Of Opioid Addiction Treatment?

Published

on

Axim Biotechnologies Inc

Axim Biotechnologies Inc (OTCMKTS:AXIM) reported that it has filed with the USPTO a patent of invention that comprises a chewing gum composition having controlled release of opioid and cannabinoids and/or antagonists for dependence treatment and/or addiction. The chewing gum may work as a means for treatment of chronic pain.

The details

George E. Anastassov, the CEO of Axim, reported that opioid addiction is a grave international concern that impacts the health, economic and social welfare of all societies. The treatment of opioid addiction relies on numerous techniques. One of these treatments is the replacement therapy, in which an opioid is substituted with another less addictive and less potent opioid that reduces withdrawal symptoms and curbs the craving, while maintaining the mental state of patient like the person can still function normally.

Moreover, by offering replacement opioids like antagonists and/or opioid agonists and CBDs in a chewing gum form, people may avoid harmful impacts caused by smoking, injection and other delivery mechanisms. The act of chewing is known to be de-stressing, neuroprotective as it encourages the release of reward hormones like serotonin and dopamine, and enhances oral health.

Dr. Anastassov added that it is another great achievement for Axim. They consider they are the first to submit patent application on utilizing chewing gum as the delivery mechanism for opioids and combination of cannabinoids and opioids. With this filing, they are one step closer toward venturing into the $100 billion industry in pain management.

An agonist can be defined as a chemical that attaches to a receptor and activates it to produce a biological response. At the same time full opioid agonists trigger the opioid receptors in the human brain leading in the full opioid effect.

An antagonist marks as a chemical that dampens or blocks agonist-mediated responses. It should be known that opioid antagonists obstruct opioids by binding to the same opioid receptors and it is done without activating them.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement